Abstract:Clinical development of antibiotics with novel mechanisms of action to kill pathogenic bacteria is challenging, in part, due to the inevitable emergence of resistance. A phenomenon of potential clinical importance that is broadly overlooked in preclinical development is heteroresistance, an often-unstable phenotype in which sub-populations of bacterial cells show decreased antibiotic susceptibility relative to the dominant population. Here, we describe a new globomycin analog, G0790, with potent activity against the Escherichia coli type II signal peptidase LspA and uncover two novel resistance mechanisms to G0790 in the clinical uropathogenic E. coli strain CFT073. Building on the previous finding that complete deletion of Lpp, the major Gram-negative outer membrane lipoprotein, leads to globomycin resistance, we also find that an unexpectedly modest decrease in Lpp levels mediated by insertion-based disruption of regulatory elements is sufficient to confer G0790 resistance and increase sensitivity to serum killing. In addition, we describe a heteroresistance phenotype mediated by genomic amplifications of lspA that result in increased LspA levels sufficient to overcome inhibition by G0790 in culture. These genomic amplifications are highly unstable and are lost after as few as two subcultures in the absence of G0790, which places amplification-containing resistant strains at high risk of being misclassified as susceptible by routine antimicrobial susceptibility testing. In summary, our study uncovers two vastly different mechanisms of resistance to LspA inhibitors in E. coli and emphasizes the importance of considering the potential impact of unstable and heterogenous phenotypes when developing antibiotics for clinical use. IMPORTANCE Despite increasing evidence suggesting that antibiotic heteroresistance can lead to treatment failure, the significance of this phenomena in the clinic is not well understood, because many clinical antibiotic susceptibility testing approaches lack the resolution needed to reliably classify heteroresistant strains. Here we present G0790, a new globomycin analog and potent inhibitor of the Escherichia coli type II signal peptidase LspA. We demonstrate that in addition to previously known mechanisms of resistance to LspA inhibitors, unstable genomic amplifications containing lspA can lead to modest yet biologically significant increases in LspA protein levels that confer a heteroresistance phenotype.

Novel Inhibitors Ofe. Colilipoprotein Diacylglyceryl Transferase Are Insensitive to Resistance Caused Bylppdeletion

Novel inhibitors of E. coli lipoprotein diacylglyceryl transferase are insensitive to resistance caused by lpp deletion

Inhibition of <i>Escherichia coli</i> Lipoprotein Diacylglyceryl Transferase Is Insensitive to Resistance Caused by Deletion of Braun's Lipoprotein

Deletion of a Previously Uncharacterized Lipoprotein Lirl Confers Resistance to an Inhibitor of Type II Signal Peptidase in Acinetobacter Baumannii

Unstable Mechanisms of Resistance to Inhibitors of Escherichia Coli Lipoprotein Signal Peptidase.

Disrupting Gram-negative bacterial outer membrane biosynthesis through inhibition of the lipopolysaccharide transporter MsbA.

Optimization Of Globomycin Analogs As Novel Gram-Negative Antibiotics

A screen for cell envelope stress uncovers an inhibitor of prolipoprotein diacylglyceryl transferase, Lgt, in Escherichia coli

Deletion of Lytic Transglycosylases Increases Beta-Lactam Resistance in Shewanella Oneidensis.

Common and varied molecular responses of Escherichia coli to five different inhibitors of the lipopolysaccharide biosynthetic enzyme LpxC

A new antibiotic traps lipopolysaccharide in its intermembrane transporter

Peptidoglycan Association of Murein Lipoprotein is Required for KpsD-Dependent Group 2 Capsular Polysaccharide Expression and Serum Resistance in a Uropathogenic Escherichia Coli Isolate

Decreased Expression of LamB and Odp1 Complex is Crucial for Antibiotic Resistance in Escherichia Coli.

Structure of the essential inner membrane lipopolysaccharide-PbgA complex

A High-Throughput–Compatible Fluorescence Anisotropy-Based Assay for Competitive Inhibitors of Escherichia Coli UDP-N-Acetylglucosamine Acyltransferase (Lpxa)

A pathway-directed positive growth restoration assay to facilitate the discovery of lipid A and fatty acid biosynthesis inhibitors in Acinetobacter baumannii

The Prediction of LptA and LptC Protein-Protein Interactions and Virtual Screening for Potential Inhibitors

Novel inhibitor discovery and the conformational analysis of inhibitors of listeriolysin O via protein-ligand modeling

Suppressors of lapC Mutation Identify New Regulators of LpxC, Which Mediates the First Committed Step in Lipopolysaccharide Biosynthesis

Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (lpxc) Against Gram-Negative Bacteria

The Lactococcal dgkB (yecE) and dxsA Genes for Lipid Metabolism Are Involved in the Resistance to Cell Envelope-Acting Antimicrobials